Stephen L. Forster (Steve)

Steve Forster focuses on pharmaceutical drug pricing, government price reporting, and reimbursement. With in-house experience at global pharmaceutical companies and the government, Steve combines extensive regulatory insight with deep industry knowledge to support global pharmaceutical clients at all stages of a product life cycle.

Steve frequently advises clients, market entrants, and investors on price reporting and other compliance obligations related to Medicaid, Medicare, Veterans Affairs, the 340B Drug Pricing Program, and state price transparency reporting obligations. Certification and submission of accurate price reporting metrics are critical to program compliance and securing reimbursement, and clients regularly seek Steve's advice in connection with reporting AMP (average manufacturer price) and Best Price under the Medicaid Drug Rebate Program, ASP (average sales price) under Medicare Part B, and 340B Drug Pricing Program requirements. His practice also covers the federal Anti-Kickback Statute and the False Claims Act.

As the former lead counsel of pricing and commercial access strategy at a global pharmaceutical company, Steve advised and negotiated channel, trade, distribution, specialty pharmacy, pharmacy benefit management (PBM), and group purchasing organization (GPO) contracts. And he supported strategic pricing and contracting engagements, product launches, compliance, and long-term business strategies.

Steve has worked with many pharma product types, enabling him to build a robust understanding of commercial and government distribution programs, risk evaluation and mitigation strategies (REMS) compliance, and specialty limited distribution products. He also handles non-IP-related litigation and government inquiries, including those involving the federal Food, Drug, and Cosmetic Act.

Steve previously served as an attorney at the U.S. Drug Enforcement Administration (DEA) and with the Virginia Office of the Attorney General.